Sandra Beaver Sells 1,586 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 1,586 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.85, for a total value of $17,208.10. Following the sale, the chief financial officer now owns 146,916 shares in the company, valued at $1,594,038.60. The trade was a 1.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $11.09 on Friday. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm has a market capitalization of $702.23 million, a PE ratio of -12.19 and a beta of 1.27. Evolus, Inc. has a 1-year low of $9.80 and a 1-year high of $17.82. The business’s fifty day moving average price is $13.46 and its two-hundred day moving average price is $13.73.

Analyst Ratings Changes

Several research firms recently issued reports on EOLS. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Friday, September 13th. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Finally, Barclays increased their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th.

Institutional Trading of Evolus

Large investors have recently modified their holdings of the company. Essex Investment Management Co. LLC boosted its stake in Evolus by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after purchasing an additional 1,111 shares during the period. Arizona State Retirement System grew its stake in shares of Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after purchasing an additional 1,253 shares in the last quarter. Creative Planning increased its holdings in shares of Evolus by 23.7% during the third quarter. Creative Planning now owns 15,451 shares of the company’s stock valued at $250,000 after purchasing an additional 2,963 shares during the period. Sei Investments Co. raised its stake in shares of Evolus by 9.8% during the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock valued at $367,000 after purchasing an additional 3,020 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in Evolus in the second quarter worth about $43,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.